Comparative Pharmacology
Head-to-head clinical analysis: ACTIFED versus CORPHED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIFED versus CORPHED.
ACTIFED vs CORPHED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Corbined (idarucizumab) is a humanized monoclonal antibody fragment that binds to dabigatran with high affinity, neutralizing its anticoagulant effect. It acts as a specific reversal agent for dabigatran.
1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.
10-20 mg orally twice daily; maximum 60 mg/day.
None Documented
None Documented
Triprolidine: 3.2 hours; Pseudoephedrine: 5–8 hours (pH-dependent: alkaline urine prolongs). Terminal half-life for clinical use typically 4–6 hours.
Terminal half-life 3-4 hours; prolonged in renal impairment (up to 15 hours)
Renal: 80% (20% unchanged, 60% as metabolites). Fecal: 20% (unchanged and metabolites). Active tubular secretion of pseudoephedrine.
Renal (70-80% as unchanged drug), biliary/fecal (20-30%)
Category C
Category C
Decongestant/Antihistamine Combination
Antihistamine/Decongestant